Ensysce Biosciences Inc Dossier
Qualitative Analysis
Business overview
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage pharmaceutical company dedicated to developing innovative solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. The company's proprietary technology platforms include Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®). TAAP™ is designed to create prodrugs that remain pharmacologically inactive until exposed to the digestive enzyme trypsin, preventing common methods of abuse such as crushing, chewing, snorting, or injecting. MPAR® adds an extra layer of safety by incorporating a trypsin inhibitor (nafamostat) to limit active drug release if an excessive number of pills are ingested, thereby preventing accidental or intentional oral overdoses. Ensysce's lead drug candidate is PF614, a TAAP™ extended-release oxycodone prodrug currently in Phase 3 clinical development, and PF614-MPAR®, which has received FDA Breakthrough Therapy designation.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
The Board of Directors initiated a formal review of a broad range of strategic alternatives intended to enhance shareholder value and support the continued advancement of the Company's proprietary technologies.
Expected impact: May include strategic partnerships, licensing arrangements, capital formation transactions, business combinations, asset sales, or other corporate transactions.
Execution of the pivotal PF614-301 Phase 3 clinical trial for lead drug candidate PF614, a Trypsin-Activated Abuse Protection (TAAP) extended-release oxycodone.
Expected impact: Aims to establish clinical efficacy and safety to support a New Drug Application (NDA) for severe pain treatment.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Partnered to ensure rigorous trial execution of the pivotal Phase 3 clinical program for PF614.
Terms: Terms not publicly disclosed.
Supports the development of the MPAR platform and OUD candidate PF9001 through multi-year HEAL grants.
Terms: Provides non-dilutive funding, including a second multi-year grant totaling over $25 million to date, with installments of $5 million annually.